Your browser doesn't support javascript.
loading
miR-224 Is Significantly Upregulated and Targets Caspase-3 and Caspase-7 During Colorectal Carcinogenesis.
Fassan, Matteo; Cui, Ri; Gasparini, Pierluigi; Mescoli, Claudia; Guzzardo, Vincenza; Vicentini, Caterina; Munari, Giada; Loupakis, Fotios; Lonardi, Sara; Braconi, Chiara; Scarpa, Marco; D'Angelo, Edoardo; Pucciarelli, Salvatore; Angriman, Imerio; Agostini, Marco; D'Incá, Renata; Farinati, Fabio; Gafà, Roberta; Lanza, Giovanni; Frankel, Wendy L; Croce, Carlo Maria; Valeri, Nicola; Rugge, Massimo.
Afiliação
  • Fassan M; Department of Medicine (DIMED), University of Padua, Padua, Italy.
  • Cui R; Human Cancer Genetics Program, The Ohio State University Comprehensive Cancer Center, Columbus, OH; School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, 325035, China.
  • Gasparini P; Human Cancer Genetics Program, The Ohio State University Comprehensive Cancer Center, Columbus, OH.
  • Mescoli C; Department of Medicine (DIMED), University of Padua, Padua, Italy.
  • Guzzardo V; Department of Medicine (DIMED), University of Padua, Padua, Italy.
  • Vicentini C; ARC-NET Research Center, University of Verona, Verona, Italy.
  • Munari G; Department of Medicine (DIMED), University of Padua, Padua, Italy.
  • Loupakis F; Oncology Unit, Istituto Oncologico Veneto, IOV-IRCCS, Padua, Italy.
  • Lonardi S; Oncology Unit, Istituto Oncologico Veneto, IOV-IRCCS, Padua, Italy.
  • Braconi C; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, UK; Department of Medicine, The Royal Marsden NHS Trust, London, UK.
  • Scarpa M; Department of Surgical Oncology and Gastroenterology (DiSCOG), University of Padua, Padua, Italy.
  • D'Angelo E; Department of Surgical Oncology and Gastroenterology (DiSCOG), University of Padua, Padua, Italy.
  • Pucciarelli S; Department of Surgical Oncology and Gastroenterology (DiSCOG), University of Padua, Padua, Italy.
  • Angriman I; Department of Surgical Oncology and Gastroenterology (DiSCOG), University of Padua, Padua, Italy.
  • Agostini M; Department of Surgical Oncology and Gastroenterology (DiSCOG), University of Padua, Padua, Italy.
  • D'Incá R; Department of Surgical Oncology and Gastroenterology (DiSCOG), University of Padua, Padua, Italy.
  • Farinati F; Department of Surgical Oncology and Gastroenterology (DiSCOG), University of Padua, Padua, Italy.
  • Gafà R; Department of Pathology, University of Ferrara, Ferrara, Italy.
  • Lanza G; Department of Pathology, University of Ferrara, Ferrara, Italy.
  • Frankel WL; Department of Pathology, The Ohio State University Comprehensive Cancer Center, Columbus, OH.
  • Croce CM; Human Cancer Genetics Program, The Ohio State University Comprehensive Cancer Center, Columbus, OH.
  • Valeri N; Department of Medicine, The Royal Marsden NHS Trust, London, UK; Molecular Pathology Division, Institute of Cancer Research, London and Sutton, UK. Electronic address: nicola.valeri@icr.ac.uk.
  • Rugge M; Department of Medicine (DIMED), University of Padua, Padua, Italy.
Transl Oncol ; 12(2): 282-291, 2019 Feb.
Article em En | MEDLINE | ID: mdl-30448733
ABSTRACT
miR-224 has recently emerged as a driver oncomiR in sporadic colorectal carcinogenesis, but its pathogenetic role is still controversial. A large phenotypical and molecularly characterized series of preinvasive and invasive colorectal lesions was investigated for miR-224 expression by qRT-PCR and in situ hybridization. The caspase-3 and caspase-7 status was also assessed and correlated to miR-224 dysregulation. miR-224 was significantly upregulated during the adenoma-carcinoma sequence and in the context of inflammatory bowel disease dysplastic lesions, whereas its expression was significantly downregulated among BRAF-mutated tumors and in the presence of a DNA mismatch repair deficiency. miR-224 targets caspase-3 and caspase-7 in colorectal cancer, and this inverse relation was already evident from the earliest phases of transformation in intestinal mucosa. The miR-224/caspases axis may represent an interesting field of study for innovative biomarkers/therapeutics for BRAF-mutated/DNA mismatch repair-deficient tumors.

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2019 Tipo de documento: Article